Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

To assess the association between inclusion of a macrolide in a beta-lactam-based empirical antibiotic regimen and mortality among patients with bacteremic pneumococcal pneumonia, 10 years of data from a database were analyzed. The total available set of putative prognostic factors was subjected to stepwise logistic regression, with in-hospital death as the dependent variable. Of the 409 patients analyzed, 238 (58%) received a beta-lactam plus a macrolide and 171 (42%) received a beta-lactam without a macrolide. Multivariate analysis revealed 4 variables to be independently associated with death: shock (P<.0001), age of >or=65 years (P=.02), infections with pathogens that have resistance to both penicillin and erythromycin (P=.04), and no inclusion of a macrolide in the initial antibiotic regimen (P=.03). For patients with bacteremic pneumococcal pneumonia, not adding a macrolide to a beta-lactam-based initial antibiotic regimen is an independent predictor of in-hospital mortality. However, only a randomized study can definitively determine whether this association is due to a real effect of macrolides.

[1]  Noel B. Solis.  Biology and Ecology , 2004, Australian Water Bugs. (Hemiptera - Heteroptera, Gerromorpha & Nepomorpha).

[2]  J. Hoyt,et al.  Macrolide antibiotics and pulmonary inflammation. , 2001, FEMS microbiology letters.

[3]  R. Wunderink,et al.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. , 2001, Archives of internal medicine.

[4]  M. Niederman,et al.  Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997. , 2001, Chest.

[5]  R. Dessau,et al.  Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. , 2000, The Journal of antimicrobial chemotherapy.

[6]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Claude Carbón,et al.  Relationship between Capsular Type, Penicillin Susceptibility, and Virulence of Human Streptococcus pneumoniae Isolates in Mice , 2000, Antimicrobial Agents and Chemotherapy.

[8]  B. Guglielmo,et al.  Antimicrobial Selection for Hospitalized Patients with Presumed Community-Acquired Pneumonia: A Survey of Nonteaching US Community Hospitals , 2000, The Annals of pharmacotherapy.

[9]  M. Fine,et al.  Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. , 1999, Archives of internal medicine.

[10]  J E Stahl,et al.  Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. , 1999, Archives of internal medicine.

[11]  M. Mufson,et al.  Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. , 1999, The American journal of medicine.

[12]  A. Ruiz-González,et al.  Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. , 1999, The American journal of medicine.

[13]  J. Bartlett,et al.  Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. , 1998, Chest.

[14]  M. Kolczak,et al.  Incidence of Community-Acquired Pneumonia Requiring Hospitalization Results of a Population-Based Active Surveillance Study in Ohio , 1997 .

[15]  M. Kolczak,et al.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. , 1997, Archives of internal medicine.

[16]  P. Saikku,et al.  Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. , 1996, Thorax.

[17]  R. Rodríguez-Roisín,et al.  Severe community-acquired pneumonia. Epidemiology and prognostic factors. , 1991, The American review of respiratory disease.

[18]  J. A. Cuello,et al.  Severe community-acquired pneumonia. Etiology, prognosis, and treatment. , 1990, The American review of respiratory disease.

[19]  W. R. Mccabe,et al.  Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients , 1980 .

[20]  J. Lewis,et al.  Gram-negative bacteremia. , 1969, The Johns Hopkins medical journal.

[21]  G. Jackson,et al.  Gram-Negative Bacteremia: I. Etiology and Ecology , 1962 .